Maynard Um
-
-
-
-
-
-
-
Theralase(R) Announces $5 Million Brokered LIFE Offering
-
-
-
-
-
-
-
Theralase(R) Announces $4 Million Brokered LIFE Offering
-
-
-
-
-
-
-
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
-
-
-
-
-
-
-
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
-
-
-
-
-
-
-
Theralase(R) Releases 3Q2025 Financial Statements
-
-
-
-
-
-
-
Theralase(R) Closes Non-Brokered Private Placement
-
-
-
-
-
-
-
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
-
479,792 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


